Kyverna Therapeutics KYTX Income Statement (2023-2026)

NASDAQ KYTX
$8.29 -0.06 (-0.72%)
As of: Sep 4, 2026 · 2:15 PM EDT
Reported Financials

Kyverna Therapeutics Quarterly Income Statement

Periods 14 quarters
Latest Jun 2026

Kyverna Therapeutics reported net income of -$38.37M for the quarter ended Jun 2026. This income statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.) 1.02M0.63M0.66M0.67M23.75M43.15M43.17M43.21M43.22M43.24M43.79M44.26M60.53M61.57M
Operating items
Research & DevelopmentR&D 8.71M10.40M13.64M17.16M22.48M27.32M29.19M33.48M37.43M35.82M30.46M30.01M30.07M24.79M
Selling, General & AdministrativeSG&A 2.73M2.90M2.64M4.21M6.88M6.11M9.58M7.56M9.97M8.59M8.27M9.27M11.29M14.77M
Operating ExpensesOpex 11.45M13.30M16.28M21.38M29.36M33.44M38.77M41.04M47.41M44.41M38.73M39.28M41.37M39.56M
Operating IncomeOp. Inc -11.45M-13.30M-16.28M-21.38M-29.36M-33.44M-38.77M-41.04M-47.41M-44.41M-38.73M-39.28M-41.37M-39.56M
EBIT -11.45M-13.30M-16.28M-21.38M-29.36M-33.44M-38.77M-41.04M-47.41M-44.41M-38.73M-39.28M-41.37M-39.56M
Non-operating items
Non Operating Interest Expenses 0.04M0.05M0.05M0.05M0.04M0.04M0.03M0.03M0.03M0.01M0.01M0.44M0.67M0.67M
Interest & Investment IncomeInt & Inv Inc 0.35M0.26M0.88M0.79M2.73M4.69M4.36M3.58M2.83M2.36M2.00M1.91M2.33M1.93M
Other Non Operating IncomeOther Non Op Inc. -0.00M-0.01M-0.01M-0.03M-0.03M-0.02M-0.04M0.00M-0.03M-0.02M-0.05M0.02M-0.02M-0.02M
Non Operating IncomeNon Op. Inc. 0.30M0.21M0.82M0.71M2.67M4.63M4.28M3.55M2.77M2.33M1.94M1.48M1.64M1.24M
Net income details
EBT -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M-38.30M
Profit After TaxPAT -11.14M-13.09M-15.46M-20.70M-26.69M-28.80M-34.49M-37.50M-44.63M-42.10M-36.79M-37.74M-39.73M-38.37M
Income from Continuing OperationsIncome (Continuing) -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M-38.30M
Consolidated Net IncomeConsol Net Inc. -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M-38.30M
Income towards Parent CompanyParent Net Inc -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M-38.30M
Net Income towards Common StockholdersNet Income -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M-38.30M
Additional items
EPS (Basic) -12.09-20.85-23.25-30.63-1.12-0.67-0.80-0.98-1.03-0.97-0.85-0.85-0.66-0.63
EPS (Diluted) -12.09-20.85-23.25-30.63-1.12-0.67-0.80-0.98-1.03-0.97-0.85-0.85-0.66-0.63
Shares Outstanding 0.92M0.63M0.66M0.67M23.75M43.13M43.16M38.33M43.22M43.23M43.42M44.26M60.43M60.90M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 0.92M0.63M0.66M0.67M23.75M43.13M43.16M38.33M43.22M43.23M43.42M44.26M60.43M60.90M
EBITDA -11.45M-13.30M-16.28M-21.38M-29.36M-33.44M-38.77M-41.04M-47.41M-44.41M-38.73M-39.28M-41.37M-39.56M
Interest ExpensesInt Expense 0.04M0.05M0.05M0.05M0.04M0.04M0.03M0.03M0.03M0.01M0.01M0.44M0.67M0.67M